Immunome (IMNM) Enterprise Value (2019 - 2026)
Immunome's (IMNM) quarterly Enterprise Value came in at -$582.7 million in Q1 2026, down 83.63% YoY from -$3.6 billion in Q1 2025, and up 10.83% on a QoQ basis from -$653.5 million in Q4 2025.
Immunome (IMNM) Enterprise Value (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Enterprise Value data on file, last reported at -$582.7 million in Q1 2026.
- Quarterly Enterprise Value fell 83.63% year-over-year to -$582.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$582.7 million (down 83.63% YoY) and the FY2025 annual result came in at -$653.5 million, down 200.72% from the prior year.
- Enterprise Value advanced to -$582.7 million in Q1 2026, from -$653.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$20.3 million in Q4 2022 to a low of -$653.5 million in Q4 2025.
- A 5-year average of -$210.4 million and a median of -$217.3 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 58.72% — and 2024, when it plunged 624.52%.
- Tracing IMNM's Enterprise Value over 5 years: stood at -$20.3 million in 2022, then tumbled by 579.73% to -$138.1 million in 2023, then tumbled by 57.3% to -$217.3 million in 2024, then plunged by 200.72% to -$653.5 million in 2025, then gained by 10.83% to -$582.7 million in 2026.
- The last three Enterprise Value figures came in at -$582.7 million (Q1 2026), -$653.5 million (Q4 2025), and -$272.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | -520.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -520.01 Mn |
| Mar 31, 2026 | -582.69 Mn |
| Dec 31, 2025 | -653.48 Mn |
| Sep 30, 2025 | -272.64 Mn |
| Jun 30, 2025 | -268.10 Mn |
| Mar 31, 2025 | -317.31 Mn |
| Dec 31, 2024 | -217.30 Mn |
| Sep 30, 2024 | -240.13 Mn |
| Jun 30, 2024 | -278.33 Mn |
| Mar 31, 2024 | -309.71 Mn |
| Dec 31, 2023 | -138.14 Mn |
| Sep 30, 2023 | -90.64 Mn |
| Jun 30, 2023 | -38.42 Mn |
| Mar 31, 2023 | -44.42 Mn |
| Dec 31, 2022 | -20.32 Mn |
| Sep 30, 2022 | -27.08 Mn |
| Jun 30, 2022 | -34.65 Mn |
| Mar 31, 2022 | -42.88 Mn |
| Dec 31, 2021 | -49.23 Mn |
| Sep 30, 2021 | -56.24 Mn |